A Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)
To evaluate safety and tolerability of lambda over a 48-week treatment period in HDV patients.
100 Clinical Results associated with EIT Pharma, Inc.
0 Patents (Medical) associated with EIT Pharma, Inc.
100 Deals associated with EIT Pharma, Inc.
100 Translational Medicine associated with EIT Pharma, Inc.